Gossamer Bio (GOSS)

Company Profile

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

Company profile

Ticker

GOSS

Exchange

NASDAQ

Website

www.gossamerbio.com

CEO

Sheila Gujrathi

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001728117

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

GB002, Inc. • GB004, Inc. • Gossamer Bio Services, Inc. ...

IRS number

475461709

GOSS stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$6.14

Low target

$2.00

High target

$10.00

Latest filings (excl ownership)

View all

3 Nov 22

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

3 Nov 22

8-K

Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

9 Aug 22

Automatic shelf registration

9 Aug 22

$120.04M in equity, sold $120.04M, 23 investors

18 Jul 22

8-K

Gossamer Bio Announces $120 million Private Placement Financing

13 Jul 22

8-K

Submission of Matters to a Vote of Security Holders

10 Jun 22

8-K

Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update

10 May 22

Transcripts

View all

GOSS

Earnings call transcript

2021 Q3

9 Nov 21

GOSS

Earnings call transcript

2021 Q2

10 Aug 21

GOSS

Earnings call transcript

2020 Q4

27 Feb 21

GOSS

Earnings call transcript

2020 Q3

10 Nov 20

GOSS

Earnings call transcript

2020 Q1

12 May 20

GOSS

Earnings call transcript

2019 Q3

12 Nov 19

GOSS

Earnings call transcript

2019 Q2

10 Aug 19

GOSS

Earnings call transcript

2019 Q1

14 May 19

Latest ownership filings

View all

MILLENNIUM MANAGEMENT LLC

4 Jan 23

SC 13G

MILLENNIUM MANAGEMENT LLC

Financial summary

Financial statements Chart GOSS financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	153.48 mm	153.48 mm	153.48 mm	153.48 mm	153.48 mm	153.48 mm
Cash burn (monthly)	(no burn)	5.01 mm	18.67 mm	17.99 mm	12.33 mm	14.98 mm
Cash used (since last report)	n/a	21.52 mm	80.30 mm	77.37 mm	53.03 mm	64.43 mm
Cash remaining	n/a	131.95 mm	73.18 mm	76.11 mm	100.45 mm	89.04 mm
Runway (months of cash)	n/a	26.4	3.9	4.2	8.1	5.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

GOSS institutional ownership history Ownership history

3.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1	130	-99.2%
Opened positions	0	20	EXIT
Closed positions	129	29	+344.8%
Increased positions	0	34	EXIT
Reduced positions	0	50	EXIT

13F shares	Current	Prev Q	Change
Total value	32.11 mm	963.18 mm	-96.7%
Total shares	3.32 mm	66.54 mm	-95.0%
Total puts	0.00	69.00 k	EXIT
Total calls	0.00	1.22 mm	EXIT
Total put/call ratio	–	0.1	–

Largest owners	Shares	Value	Change
Omega Fund V	3.32 mm	$32.11 mm	0.0%

Largest transactions	Bought/sold	Change
Hillhouse Capital Advisors	-7.42 mm	EXIT
Vanguard	-5.85 mm	EXIT
BLK Blackrock	-5.17 mm	EXIT
STT State Street	-3.88 mm	EXIT
FHI Federated Hermes	-3.53 mm	EXIT
Octagon Capital Advisors	-2.76 mm	EXIT
Boxer Capital	-2.46 mm	EXIT
Artal	-2.36 mm	EXIT
Kynam Capital Management	-2.35 mm	EXIT
Citadel Advisors	-2.28 mm	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GOSS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
7 Dec 22	Hasnain Faheem	Stock Option Common Stock	Grant	Acquire A	No	No	2.16	544,500	1.18 mm	544,500
7 Dec 22	Giraudo Bryan	Stock Option Common Stock	Grant	Acquire A	No	No	2.16	211,500	456.84 k	211,500
7 Dec 22	Christian Waage	Stock Option Common Stock	Grant	Acquire A	No	No	2.16	157,500	340.20 k	157,500
7 Dec 22	Richard Aranda	Stock Option Common Stock	Grant	Acquire A	No	No	2.16	157,500	340.20 k	157,500
7 Dec 22	Caryn Peterson	Stock Option Common Stock	Grant	Acquire A	No	No	2.16	157,500	340.20 k	157,500